(Q35111596)

6 August 2017

1 reference

title

Research issues in the study of difficult-to-treat depression (English)

1 reference

6 August 2017

1

A John Rush

2 references

ORCID Public Data File 2021

6 August 2017

Michael E Thase

2

1 reference

6 August 2017

Sanjay Dubé

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

published in

Biological Psychiatry

1 reference

6 August 2017

volume

53

1 reference

6 August 2017

issue

8

1 reference

6 August 2017

page(s)

743-753

1 reference

The Relationship of Personality to Affective Disorders

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Lost human capital from early-onset chronic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

The importance of Axis II in patients with major depression. A controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

A rating scale for depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Development of a Rating Scale for Primary Depressive Illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Psychosocial and physical correlates of chronic depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Assessing personality: effects of the depressive state on trait measurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Sertraline versus imipramine to prevent relapse in chronic depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

A New Depression Scale Designed to be Sensitive to Change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Comorbidity of axis I and axis II disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Remission and residual symptomatology in major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Residual symptoms after partial remission: an important outcome in depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Prevention of relapse in residual depression by cognitive therapy: a controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

DSM-III-R axis II comorbidity in dysthymia and major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Bipolar II and unipolar comorbidity in 153 outpatients with social phobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

How accurate are patients in reporting their antidepressant treatment history?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Resistance to antidepressant medications and short-term clinical response to ECT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

The search for determinants of chronic depression: a review of six factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Does pretreatment anxiety predict response to either bupropion SR or sertraline?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

The inventory for depressive symptomatology (IDS): Preliminary findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

The Inventory of Depressive Symptomatology (IDS): psychometric properties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Methodological issues in developing new acute treatments for patients with bipolar illness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

A novel augmentation strategy for treating resistant major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Which depressed patients respond to nefazodone and when?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

Lamotrigine as an augmentation agent in treatment-resistant depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Personal and psychosocial risk factors for physical and mental health outcomes and course of depression among depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Life stressors, social resources, coping, and the 4-year course of unipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900088-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(03)00088-X

1 reference

6 August 2017

1 reference